Sita-Ex-Cs-SeNPs nanoplatform achieves 98% sitagliptin encapsulation for targeted subcutaneous β-cell delivery
Background
Effective management of diabetes requires strategies that both stimulate β-cell growth and prevent their apoptosis. While sitagliptin is a well-established therapeutic for type 2 diabetes, its clinical utility is often limited by suboptimal oral bioavailability and a lack of site-specific delivery to the pancreas. Current standard-of-care often involves systemic administration, which can lead to off-target effects. This research addresses the critical gap in targeted delivery, aiming to enhance sitagliptin's efficacy by leveraging GLP-1 receptor affinity and selenium's antioxidant properties for synergistic β-cell preservation.
Study Design
Researchers developed Sita-Ex-Cs-SeNPs, a subcutaneous nanocarrier system, by encapsulating sitagliptin within chitosan-selenium nanoparticles and conjugating them with exenatide. The ionotropic gelation technique was employed for the encapsulation and integration of the components into a stable delivery system. The study focused on in vitro assessment, characterizing the physicochemical properties and drug release kinetics of the nanoparticles. Analytical techniques such as DSC, PXRD, and FTIR were used to confirm sitagliptin's state and successful peptide conjugation.
Results
The developed Sita-Ex-Cs-SeNPs exhibited a spherical architecture with an average diameter of 314.1 nm and a zeta potential of +18.7 mV, indicating good stability. A high encapsulation efficiency of 98% was achieved for sitagliptin. Analytical data from DSC and PXRD confirmed that sitagliptin transitioned to an amorphous state within the nanoparticles, which can enhance solubility and absorption. FTIR analysis successfully validated the conjugation of exenatide to the nanoplatform. > Release kinetics followed the Weibull model, demonstrating a controlled biphasic profile with 57% of the drug released over 24 hours, significantly extending the therapeutic window compared to the free drug. This sustained release profile is crucial for maintaining consistent therapeutic levels.
Key Findings
- Sita-Ex-Cs-SeNPs nanoparticles were successfully prepared with an average diameter of 314.1 nm and a zeta potential of +18.7 mV.
- A high encapsulation efficiency of 98% was achieved for sitagliptin within the nanoplatform.
- Sitagliptin transitioned to an amorphous state, and exenatide conjugation was successfully validated.
- The nanoparticles demonstrated a controlled biphasic release profile, with 57% of the drug released over 24 hours.
- The sustained release profile significantly extends the therapeutic window compared to free sitagliptin.
Why It Matters
This novel nanoplatform offers a promising, biocompatible approach for targeted diabetes intervention, potentially overcoming the limitations of current sitagliptin formulations. For peptide users and clinicians, a targeted subcutaneous delivery system could mean improved efficacy, reduced dosing frequency, and fewer systemic side effects by concentrating the drug at the pancreatic β-cells. The extended release profile suggests a protocol where dosing intervals could be significantly lengthened, enhancing patient adherence and convenience. This research lays the groundwork for a more efficient and patient-friendly sitagliptin delivery method, potentially allowing for lower overall doses while achieving superior therapeutic outcomes in β-cell preservation.
sitagliptin
exenatide
selenium
nanoparticles
diabetes
beta-cell-preservation